Table 2.

Objective tumor responses according to TMB, gene mutations, and the PD-L1 CPS.

Detected(%)Responder (CR or PR)Nonresponder (SD or PD)ORR (%)OR95% CIPa
TMBHigh41(91.1)2021(48.8)
Low4(8.9)04(0.0)
EGFRWild-type40(88.9)1723(42.5)(Reference)0.464
Mutant5(11.1)32(60.0)0.490.073.28
ERBB2Wild-type29(64.4)1316(44.8)(Reference)0.944
Mutant16(35.6)79(43.8)1.040.313.57
ERBB3Wild-type32(76.2)1418(43.8)(Reference)0.373
Mutant10(23.8)64(60.0)0.520.122.20
FGFR2Wild-type38(84.4)1424(36.8)(Reference)0.039
Mutant7(15.6)61(85.7)0.10.010.89
FGFR3Wild-type40(88.9)1723(42.5)(Reference)0.464
Mutant5(11.1)32(60.0)0.490.073.28
BRAFWild-type33(73.3)1518(45.5)(Reference)0.821
Mutant12(26.7)57(41.7)1.170.314.44
KRASWild-type23(51.1)914(39.1)(Reference)0.464
Mutant22(48.9)1111(50.0)0.640.202.10
PIK3CAWild-type25(55.6)1312(52.0)(Reference)0.257
Mutant20(44.4)713(35.0)2.010.606.74
PTENWild-type31(68.9)1714(54.8)(Reference)0.045
Mutant14(31.1)311(21.4)4.451.0319.20
STK11Wild-type36(80.0)1719(47.2)(Reference)0.457
Mutant9(20.0)36(33.3)1.790.398.29
MTORWild-type33(73.3)1320(39.4)(Reference)0.263
Mutant12(26.7)75(58.3)0.460.121.78
APCWild-type30(66.7)1317(43.3)(Reference)0.832
Mutant15(33.3)78(46.7)0.870.253.04
CTNNB1Wild-type37(82.2)1423(37.8)(Reference)0.071
Mutant8(17.8)62(75.0)0.20.041.15
TCF7Wild-type32(78.0)1319(40.6)(Reference)0.063
Mutant9(22.0)72(77.8)0.20.031.09
ARID1AWild-type11(24.4)47(36.4)(Reference)0.536
Mutant34(75.6)1618(47.1)0.640.162.61
TP53Wild-type30(66.7)1119(36.7)(Reference)0.142
Mutant15(33.3)96(60.0)0.390.111.38
ATMWild-type29(70.7)1415(48.3)(Reference)0.920
Mutant12(29.3)66(50.0)0.930.243.58
NOTCH1Wild-type25(55.6)817(32.0)(Reference)0.064
Mutant20(44.4)128(60.0)0.310.091.07
NOTCH2Wild-type34(82.9)1519(44.1)(Reference)0.203
Mutant7(17.1)52(71.4)0.320.051.86
NOTCH3Wild-type27(65.9)1314(48.1)(Reference)0.910
Mutant14(34.1)77(50.0)0.930.263.38
FBXW7Wild-type31(68.91516(48.4)(Reference)0.430
Mutant14(31.1)59(35.7)1.690.466.20
BRCA1Wild-type39(86.7)1920(48.7)(Reference)0.172
Mutant6(13.3)15(16.7)4.750.5144.50
BRCA2Wild-type33(73.3)1419(42.4)(Reference)0.652
Mutant12(26.7)66(50.0)0.740.202.77
ATRWild-type30(73.2)1713(56.7)(Reference)0.105
Mutant11(26.8)38(27.3)3.490.7715.80
POLEWild-type32(78.0)1319(40.6)(Reference)0.063
Mutant9(22.0)72(77.8)0.20.031.09
HLA-AWild-type36(90.0)1719(47.2)(Reference)0.916
Mutant4(10.0)22(50.0)0.90.117.06
HLA-BWild-type32(80.0)1517(46.9)(Reference)0.874
Mutant8(20.0)44(50.0)0.880.194.16
HLA-CWild-type37(92.5)1621(43.2)(Reference)
Mutant3(7.5)30(100.0)Not available
JAK1Wild-type28(66.7)1315(46.4)(Reference)0.827
Mutant14(33.3)77(50.0)0.870.243.13
B2MWild-type31(77.5)1318(41.9)(Reference)0.073
Mutant9(22.5)72(77.8)0.210.041.16
CDKN1AWild-type39(95.1)1920(48.7)(Reference)0.972
Mutant2(4.9)11(50.0)0.950.0616.30
CDKN2AWild-type39(86.7)1722(43.6)(Reference)0.769
Mutant6(13.3)33(50.0)0.770.144.32
CCNE1Wild-type43(95.6)1924(44.2)(Reference)0.872
Mutant2(4.4)11(50.0)0.790.0513.50
CCND1Wild-type42(93.3)1725(40.5)(Reference)
Mutant3(6.7)30(100.0)Not available
PD-L1 CPSCPS < 113(28.9)67(46.2)(Reference)
1 ≤ CPS < 106(13.3)24(33.3)1.710.2312.900.601
CPS ≥ 1026(57.8)1214(46.2)10.263.801.000
  • Abbreviations: ECOG, Eastern Cooperative Oncology Group; PS, Performance status; PD, progressive disease; PD-L1, programmed death ligand 1.

  • aP values were calculated using the logistic regression method.